Research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
In rodents and in humans the concentration GHR mRNA and the concentration of GHBP in the maternal circulation are dramatically increased during pregnancy. This is considered likely to control the availability of GH for binding to GH receptors in the maternal tissues during pregnancy.
== Biochemistry == LTB4 is a leukotriene involved in inflammation. It is produced from leukocytes in response to inflammatory mediators and is able to induce the adhesion and activation of leukocytes on the endothelium, allowing them to bind to and cross it into the tissue. In neutrophils, it is also a potent chemoattractant, and is able to induce the formation of reactive oxygen species and the release of lysosomal enzymes by these cells. It is synthesized by leukotriene-A4 hydrolase from leukotriene A4.
All over the land of Rus', i.e., among the Cossacks, we have noticed a remarkable feature which made us marvel; all of them, with the exception of only a few among them, even the majority of their wives and daughters, can read and know the order of the church-services as well as the church melodies. Besides that, their priests take care and educate the orphans, not allowing them to wander in the streets ignorant and unattended.
Despite initial successes, however, Gericke realized that the time was not yet ripe for the general technical application and commercial use of hydroponics for producing crops. He also wanted to make sure all aspects of hydroponic cultivation were researched and tested before making any of the specifics available to the public. Reports of Gericke's work and his claims that hydroponics would revolutionize plant agriculture prompted a huge number of requests for further information. Gericke had been denied use of the university's greenhouses for his experiments due to the administration's skepticism, and when the university tried to compel him to release his preliminary nutrient recipes developed at home, he requested greenhouse space and time to improve them using appropriate research facilities. While he was eventually provided greenhouse space, the university assigned Hoagland and Arnon to re-evaluate Gericke's claims and show his formula held no benefit over soil grown plant yields, a view held by Hoagland. Because of these irreconcilable conflicts, Gericke left his academic position in 1937 in a climate that was politically unfavorable and continued his research independently in his greenhouse. In 1940, Gericke, whose work is considered to be the basis for all forms of hydroponic growing, published the book, Complete Guide to Soilless Gardening. Therein, for the first time, he published his basic formulas involving the macro- and micronutrient salts for hydroponically grown plants.
Environmentally friendly – reuses leftover leather without need for extra farming and use of resources Product consistency – no natural defects and minimal batch to batch variation High cutting yield – cost efficient and reducing waste Possible drawbacks include:
Sources: en.wikipedia.org
It is preferable not to invoke such powerful immuno-suppressive therapy in most cases of CH in which spontaneous regression of lesions or episodic disease activation is more likely to occur. Microscopic features of SH and CH The lesions of SH in most tissues consist of perivascular infiltrates of large histiocytes and variable populations of lymphocytes, neutrophils and eosinophils. The histiocytes frequently invade vessel walls and this may lead to vascular compromise and infarction of surrounding tissues. The widespread distribution of lesions of SH is only fully appreciated at necropsy. Histiocytic lesions have been observed in skin, lung, liver, bone marrow, spleen, peripheral and visceral lymph nodes, kidneys, testes, orbital tissues, nasal mucosa and others. In skin, the lesions of SH and CH are virtually identical — they consist of perivascular histiocytic infiltrates containing lymphocytes and other inflammatory cells in variable proportions (neutrophils, plasma cells, and occasionally eosinophils). The lesions usually involve the deep dermis and subcutis. Involvement of the superficial dermis is inconsistent and epidermotropism of the histiocytes is not observed. In CH the lesions are limited to the skin and draining lymph nodes.
== Synthesis, basic properties, and structure == The carbon atom in cyanogen bromide is bonded to bromine by a single bond and to nitrogen by a triple bond (i.e. Br−C≡N). The compound is linear and polar, but it does not spontaneously ionize in water. It dissolves in both water and polar organic solvents. Cyanogen bromide can be prepared by oxidation of sodium cyanide with bromine, which proceeds in two steps via the intermediate cyanogen ((CN)2):
==== Homozygous ==== By definition, the forms of MODY are autosomal dominant, requiring only one abnormal gene to produce the disease; the severity of the disease is moderated by the presence of a second, normal allele which presumably functions normally. However, conditions involving people carrying two abnormal alleles have been identified. Unsurprisingly, combined (homozygous) defects of these genes are much rarer and much more severe in their effects.
However, there has been another resurgence in interest in methenamine for recurrent UTI prevention since 2010 owing to increasing rates of bacterial resistance with antibiotics. Larger and higher-quality clinical trials of methenamine for UTI prevention, such as the United Kingdom ALTAR trial, have started to be published in the 2020s, and additional trials, such as the international European ImpresU trial, are also underway as of 2024.
== Mechanism == In FD, the analyte is applied as a thin film directly to the emitter, or small crystals of solid materials are placed onto the emitter. Slow heating of the emitter then begins, by passing a high current through the emitter, which is maintained at a high potential (e.g. 5 kilovolts). As heating of the emitter continues, low-vapor pressure materials get desorbed and ionized by alkali metal cation attachment.
Sources: en.wikipedia.org
It was nominated for numerous awards and won "Best VR/AR" at the 2020 Game Awards. Valve acknowledged that the audience for VR games was limited, and Gabe Newell, Valve's president, described Alyx as a long-term investment into new technologies. As of 2024, it had sold more than two million copies. In 2026, Valve ported Alyx to its standalone Steam Frame headset.
IP3, DAG, and Ca2+ are second messengers in the phosphoinositol pathway. The pathway begins with the binding of extracellular primary messengers such as epinephrine, acetylcholine, and hormones AGT, GnRH, GHRH, oxytocin, and TRH, to their respective receptors. Epinephrine binds to the α1 GTPase Protein Coupled Receptor (GPCR) and acetylcholine binds to M1 and M2 GPCR. Binding of a primary messenger to these receptors results in conformational change of the receptor. The α subunit, with the help of guanine nucleotide exchange factors (GEFS), releases GDP, and binds GTP, resulting in the dissociation of the subunit and subsequent activation. The activated α subunit activates phospholipase C, which hydrolyzes membrane bound phosphatidylinositol 4,5-bisphosphate (PIP2), resulting in the formation of secondary messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). IP3 binds to calcium pumps on ER, transporting Ca2+, another second messenger, into the cytoplasm. Ca2+ ultimately binds to many proteins, activating a cascade of enzymatic pathways.
=== Dance === Bromley has its own team of Morris dancers, The Ravensbourne Morris Men, founded in 1947 as a post-war revival team following an inaugural meeting at the then Jean's Café, which was located opposite Bromley South Station.
=== Glucocorticoids === Glucocorticoids are so named due to their effect on the carbohydrate mechanism. They promote glycogen storage in the liver. An enlarged liver is a rare side-effect of long-term steroid use in children. The classical effect of prolonged use both in adult and paediatric population is steatosis.
Ticket prices for the 2026 FIFA World Cup initially ranged from $60 for group stage matches to $6,730 for the final—an increase from the USD equivalent of $69 to $1,607 for the 2022 World Cup. However, in September 2025, FIFA confirmed it would use dynamic pricing for tickets for the first time, following the practice used in the 2025 FIFA Club World Cup. Special "hospitality" seats were made available in April 2025. An initial draw period for non-hospitality seats occurred between September 10–19, 2025, limited to Visa cardholders. A second phase ran from October 27–31, 2025, and a third phase started after the final draw of teams on December 5. Sales were capped at four tickets per person per match, and no person was able to purchase more than 40 tickets for the overall tournament. FIFA's official resale platform went live on October 2, 2025. A final "last-minute" sales phase reopened on April 22, 2026, approximately 50 days before the start of the tournament, with tickets for all 104 matches made available on a first-come, first-served basis. By that stage, more than five million tickets had been sold from an expected total exceeding six million, with additional tickets scheduled to be released in phases up to the final, subject to availability. Every city hosting the World Cup in the United States passed a law stating that ticket sales to World Cup events were exempt from state and local sales taxes.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.